Bone turnover is not influenced by serum 25-hydroxyvitamin D in pubertal healthy black and white children

We aimed to test the hypothesis that serum 25-hydroxyvitamin D3 (25(OH)D) concentration is associated with mental health and life stress measures in young adults and investigate gender and racial disparities in these associations. This study comprised 327 black and white participants. Depression, trait anxiety, perceived stress, and hostility were measured by the following validated instruments: Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), Perceived Stress Scale (PSS), and Cook–Medley Hostility Scale (CMHS). Linear regression was used to estimate correlations between serum 25(OH)D concentration and mental health measurements in the total population and in subgroups stratified by gender and race. In this sample (28.2 ± 3.1 years, 52% female, 53% black), serum 25(OH)D concentration was negatively related to BDI, STAI, PSS, total CMHS score, and the majority of CMHS subscale scores (p-values < 0.05). Stratified by gender, most of these associations remained significant only in women (p-values < 0.05). Stratified by race, higher 25(OH)D concentrations in white participants were significantly related to lower BDI, STAI, PSS, and CMHS-cynicism subscales (p-values < 0.05); 25(OH)D concentrations in the black participants were only inversely associated with CMHS and most CMHS subscales (p-values < 0.05) but not with BDI, STAI, and PSS. We present novel findings of consistent inverse relationships between serum 25(OH)D concentration and various measures of mental health and life stress. Long-term interventional studies are warranted in order to investigate the roles of vitamin D supplementation in the prevention and mitigation of depression, anxiety, and psychological stress in young adults.

Download Full-text

The Calcium-Sensing Receptor and 25-Hydroxyvitamin D-1α-Hydroxylase Interact to Modulate Skeletal Growth and Bone Turnover

Journal of Bone and Mineral Research ◽

10.1002/jbmr.3535 ◽

2018 ◽

Vol 33 (11) ◽

pp. 2082-2083 ◽

Cited By ~ 1

Author(s):

Christian Richard ◽

Rujuan Huo ◽

Rana Samadfam ◽

Isabel Bolivar ◽

Dengshun Miao ◽

...

Keyword(s):

Bone Turnover ◽

Skeletal Growth ◽

Calcium Sensing Receptor ◽

Hydroxyvitamin D ◽

Calcium Sensing ◽

25 Hydroxyvitamin D

Download Full-text

Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls

Journal of Endocrinological Investigation ◽

10.1007/s40618-015-0421-5 ◽

2016 ◽

Vol 39 (8) ◽

pp. 855-863 ◽

Cited By ~ 10

Author(s):

P. Wanby ◽

R. Nobin ◽

S.-P. Von ◽

L. Brudin ◽

M. Carlsson

Keyword(s):

Hip Fracture ◽

Bone Turnover ◽

Bone Turnover Markers ◽

Geriatric Patients ◽

Serum Levels ◽

Healthy Controls ◽

Hydroxyvitamin D ◽

25 Hydroxyvitamin D ◽

Turnover Markers ◽

Dickkopf 1

Download Full-text

Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease

American Journal of Nephrology ◽

10.1159/000499187 ◽

2019 ◽

Vol 49 (4) ◽

pp. 284-293 ◽

Cited By ~ 10

Author(s):

Stephen A. Strugnell ◽

Stuart M. Sprague ◽

Akhtar Ashfaq ◽

Martin Petkovich ◽

Charles W. Bishop

Keyword(s):

Chronic Kidney Disease ◽

Vitamin D ◽

Clinical Practice ◽

Bone Turnover ◽

Bone Turnover Markers ◽

Hydroxyvitamin D ◽

Calcium Phosphorus ◽

Safety Parameters ◽

25 Hydroxyvitamin D ◽

Turnover Markers

Background: Vitamin D repletion is recommended for secondary hyperparathyroidism (SHPT) and associated vitamin D insufficiency (VDI) in chronic kidney disease (CKD), but optimal levels of serum total 25-hydroxyvitamin D remain undefined. Clinical practice guidelines target sufficiency, whereas recent data indicate that higher levels are required to control the elevation of intact parathyroid hormone (iPTH) as CKD advances. This secondary analysis of 2 randomized controlled trials seeks to identify the minimum level of mean serum 25-hydroxyvitamin D required to control SHPT arising from VDI in stage 3 or 4 CKD. Methods: Adult subjects (n = 429) with SHPT, VDI, and stage 3 or 4 CKD were stratified by stage and treated daily with either extended-release calcifediol (ERC) or placebo in 2 identical, parallel, randomized, double-blind studies. After treatment for 26 weeks, all subjects were ranked by the level of serum total 25-hydroxyvitamin D and divided into quintiles in order to examine the relationships between the degree of vitamin D repletion and the associated changes in plasma iPTH, serum bone turnover markers, calcium, phosphorus, intact fibroblast growth factor 23 (FGF23) and vitamin D metabolites, estimated glomerular filtration rate (eGFR), and urine calcium:creatinine (Ca:Cr) ratio. Results: Progressive increases in serum 1,25-dihydroxyvitamin D and reductions in plasma iPTH and serum bone turnover markers were observed as mean posttreatment serum 25-hydroxyvitamin D rose from 13.9 ng/mL (in Quintile 1) to 92.5 ng/mL (in Quintile 5), irrespective of CKD stage. Mean serum calcium, phosphorus and FGF23, eGFR, and urine Ca:Cr ratio (collectively “safety parameters”) did not significantly change from Quintile 1. Suppression of iPTH and bone turnover markers was not observed until serum 25-hydroxyvitamin D rose to at least 50.8 ng/mL (Quintile 3). Conclusion: ERC therapy produced exposure-dependent reductions in plasma iPTH and bone turnover markers only when mean serum total 25-hydroxyvitamin D reached at least 50.8 ng/mL, indicating that current targets for vitamin D repletion therapy in CKD are too low. Gradual elevation of mean serum 25-hydroxyvitamin D to 92.5 ng/mL was not associated with significant adverse changes in safety parameters.

Download Full-text